EcoDrugPlus

Hypocretin Receptor 2

Ensembl ID : ENSDCDG00000011683
Gene Symbol: HCRTR2
3 Cross references
201 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Homolog

Ensembl ID : ENSDCDG00000024122
Gene Symbol: LOC114770011
3 Cross references
150 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Homolog

Ensembl ID : ENSDCDG00000022981
Gene Symbol: LOC114791259
3 Cross references
229 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSDCDG00000004211
Gene Symbol: IKBKB
3 Cross references
198 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 1

Ensembl ID : ENSDCDG00000021113
Gene Symbol: IMPDH1
3 Cross references
187 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1a

Ensembl ID : ENSDCDG00000033674
Gene Symbol: LOC114767170
3 Cross references
255 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 2-Like

Ensembl ID : ENSDCDG00000007805
Gene Symbol: LOC114776356
3 Cross references
202 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSDCDG00000027349
Gene Symbol: INPP5D
3 Cross references
216 Possible Orthologues:

Insulin Like Growth Factor 1 Receptor

Ensembl ID : ENSDCDG00000035269
Gene Symbol: IGF1R
3 Cross references
206 Possible Orthologues:

Insulin Receptor-Like

Ensembl ID : ENSDCDG00000027198
Gene Symbol: LOC114801770
3 Cross references
201 Possible Orthologues:

Insulin Receptor-Like

Ensembl ID : ENSDCDG00000019217
Gene Symbol: LOC114787859
3 Cross references
231 Possible Orthologues:

Insulin-Like Growth Factor 1 Receptor

Ensembl ID : ENSDCDG00000021396
Gene Symbol: LOC114765940
3 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).